BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17264302)

  • 1. Ancestry and pharmacogenetics of antileukemic drug toxicity.
    Kishi S; Cheng C; French D; Pei D; Das S; Cook EH; Hijiya N; Rizzari C; Rosner GL; Frudakis T; Pui CH; Evans WE; Relling MV
    Blood; 2007 May; 109(10):4151-7. PubMed ID: 17264302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.
    Rocha JC; Cheng C; Liu W; Kishi S; Das S; Cook EH; Sandlund JT; Rubnitz J; Ribeiro R; Campana D; Pui CH; Evans WE; Relling MV
    Blood; 2005 Jun; 105(12):4752-8. PubMed ID: 15713801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
    Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.
    Erčulj N; Kotnik BF; Debeljak M; Jazbec J; Dolžan V
    Leuk Lymphoma; 2012 Jun; 53(6):1096-104. PubMed ID: 22074251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
    Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
    D'Angelo V; Ramaglia M; Iannotta A; Crisci S; Indolfi P; Francese M; Affinita MC; Pecoraro G; Napolitano A; Fusco C; Oreste M; Indolfi C; Casale F
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1339-46. PubMed ID: 21590445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
    Rudin S; Marable M; Huang RS
    Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
    Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
    Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
    Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
    Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.
    Aslam S; Ameer S; Shabana NA; Ahmed M
    Sci Rep; 2021 Dec; 11(1):23757. PubMed ID: 34887513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia.
    Eissa DS; Ahmed TM
    Blood Coagul Fibrinolysis; 2013 Mar; 24(2):181-8. PubMed ID: 23183238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate.
    Niedzielska E; Węcławek-Tompol J; Matkowska-Kocjan A; Chybicka A
    Adv Clin Exp Med; 2013; 22(4):579-84. PubMed ID: 23986219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.
    Kamdem LK; Hamilton L; Cheng C; Liu W; Yang W; Johnson JA; Pui CH; Relling MV
    Pharmacogenet Genomics; 2008 Jun; 18(6):507-14. PubMed ID: 18496130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
    Franca R; Rebora P; Bertorello N; Fagioli F; Conter V; Biondi A; Colombini A; Micalizzi C; Zecca M; Parasole R; Petruzziello F; Basso G; Putti MC; Locatelli F; d'Adamo P; Valsecchi MG; Decorti G; Rabusin M
    Pharmacogenomics J; 2017 Jan; 17(1):4-10. PubMed ID: 26644204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
    Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia.
    ElFayoumi RI; Hagras MM; Abozenadaha A; Gari M; Abosoudah I; Shinawi T; Mirza T; Bawazir W
    Pharmacol Rep; 2019 Feb; 71(1):90-95. PubMed ID: 30508724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.